[Histoculture drug response assay guided concurrent chemoradiotherapy for lung metastasis from adrenocortical carcinoma--a case report].
A 50-year-old woman underwent surgical resection of a left adrenocortical carcinoma in April 2000. Bilateral pulmonary metastases and abdominal lymph node metastasis were detected in June 2001. After radiation therapy for the abdominal lymph node metastasis, a pulmonary metastatic lesion was thoracoscopically resected. The specimen was subjected to histoculture drug response assay (HDRA), and results revealed that this tumor was sensitive for cisplatin. We therefore performed concurrent chemoradiotherapy including cisplatin for the residual pulmonary metastatic lesion; a complete response was then obtained. Standard protocols of chemotherapy are often absent for malignant tumors, such as in this case, with low incidences. HDRA seems useful for chemotherapy agent selection in cases of rare malignant tumors.
Yoshimasu
Tatsuya
T
Dept. of Thoracic and Cardiovascular Surgery, Wakayama Medical University.
Oura
Shoji
S
Hirai
Issei
I
Kokawa
Yozo
Y
Nishida
Munehiro
M
Sasaki
Rie
R
Tanino
Hirokazu
H
Sakurai
Teruhisa
T
Okamura
Yoshitaka
Y
Inagaki
Takeshi
T
Kodama
Yoshiki
Y
Shinke
Toshiaki
T
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D018268:Adrenocortical Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D008939:Mitotane / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage
D043823:Taxoids; D000077143:Docetaxel; D008939:Mitotane; D002945:Cisplatin